Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow | ($154.7M) | ($189.0M) | ($54.9M) | ($284.9M) | ($258.7M) | ($451.1M) | ($673.5M) | $49.1M | $196.7M | ($103.0M) | ($564.4M) | ($410.7M) | $179.5M | $585.5M | $1,174.8M | $1,493.9M | $2,993.7M | $2,408.5M | $3,925.2M | $3,278.9M |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Vertex Pharmaceuticals Incorporated's last 12-month Free Cash Flow is ($1,163.8M), based on the financial report for Sep 30, 2024 (Q3 2024).
Over the last year, Vertex Pharmaceuticals Incorporated's Free Cash Flow growth was N/A. The average annual Free Cash Flow growth rates for Vertex Pharmaceuticals Incorporated have been N/A over the past three years, N/A over the past five years.